Prescription medication · Central Alpha-2 Agonist (Muscle Relaxant)

tizanidine

Also sold as Zanaflex. Tizanidine is used to treat spasticity in adults.

Data updated 2026-05-15

22,750
FDA reportsModerately reported
17
InteractionsSeveral interactions
1
Recall record

What the data shows

tizanidine (Zanaflex) is a prescription Central Alpha-2 Agonist (Muscle Relaxant), reported at a middle-of-the-pack volume (22,750 FDA reports), with 17 documented drug interactions.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

tizanidine (Zanaflex) is a prescription Central Alpha-2 Agonist (Muscle Relaxant). Tizanidine is used to treat spasticity in adults.

Tizanidine is a muscle relaxant. It is used to treat spasticity, which is when your muscles are tight or stiff.

Drug Pricing (NADAC)

Generic Price

$0.08/unit

Generic Available

Yes (14 manufacturers)

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

Compare with Another Drug → Full Side Effects Report →

What it does

Tizanidine is used to treat spasticity in adults.

Common side effects

Dry mouth, Sleepiness, Weakness

Key warnings

Tizanidine can cause low blood pressure, liver problems, and hallucinations.

The sections below are summarized in plain English from tizanidine's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Tizanidine works by affecting certain chemicals in your brain. It is an alpha-2 adrenergic agonist. This action helps to reduce muscle spasms and tightness.

Side Effects (from patient reports)

Based on 22,750 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for tizanidine, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for tizanidine each year to the FDA Adverse Event Reporting System (FAERS).

01,0002,0003,000 20042008201120142017202020232025 1,416

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where tizanidine sits

tizanidine has more FDA adverse-event reports than 57% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is tizanidine; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 22,750 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.

Total Reports

22,750

Reports Mentioning Death

1,739

7.6% of reports — not proof of cause

Hospitalization Reports

6,474

Top Indication

Product Used For Unknown Indication

Gender Distribution

Female 15,795 (75%)
Male 5,288 (25%)

Age Distribution

0–17 215
18–44 3,121
45–64 7,737
65–74 2,732
75+ 1,135

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 FATIGUE 1,693
2 PAIN 1,614
4 NAUSEA 1,529
5 FALL 1,318
6 HEADACHE 1,289
7 CHRONIC KIDNEY DISEASE 1,110
8 DIARRHOEA 1,066
9 DIZZINESS 986
11 ARTHRALGIA 814
12 ACUTE KIDNEY INJURY 808
13 VOMITING 792
14 ASTHENIA 778
15 ANXIETY 773
16 DYSPNOEA 756
17 GAIT DISTURBANCE 755

Reactions in Death Reports

DEATH 499
COMPLETED SUICIDE 485
TOXICITY TO VARIOUS AGENTS 274
CARDIO-RESPIRATORY ARREST 129
CARDIAC ARREST 108
SUSPECTED SUICIDE 106
ACUTE KIDNEY INJURY 100
CHRONIC KIDNEY DISEASE 98
RENAL FAILURE 76
RESPIRATORY ARREST 72

Reactions in Hospitalization Reports

FALL 598
PAIN 484
NAUSEA 480
PNEUMONIA 452
URINARY TRACT INFECTION 428
FATIGUE 424
DYSPNOEA 348
ACUTE KIDNEY INJURY 338
HEADACHE 337
VOMITING 337

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Tizanidine can cause low blood pressure, liver problems, and hallucinations. It can also make you very sleepy, especially if you drink alcohol or take other medicines that cause sleepiness. Your doctor should check your liver function before you start taking tizanidine and one month after you reach your highest dose. Do not stop taking tizanidine suddenly, as this can cause withdrawal symptoms.

Known Drug Interactions

( 7.2 , 12.3 ) 7.1 Strong CYP1A2 Inhibitors Concomitant use of tizanidine with strong cytochrome P450 1A2 (CYP1A2) inhibitors (e.g., fluvoxamine, ciprofloxacin) is contraindicated.

Mechanism: Ciprofloxacin stops the body from breaking down tizanidine. This can cause tizanidine to build up to dangerous levels in your system.

( 7.2 , 12.3 ) 7.1 Strong CYP1A2 Inhibitors Concomitant use of tizanidine with strong cytochrome P450 1A2 (CYP1A2) inhibitors (e.g., fluvoxamine, ciprofloxacin) is contraindicated.

Mechanism: Fluvoxamine blocks the enzyme that normally clears tizanidine from your body. This leads to much higher amounts of tizanidine in your blood than intended.

moderate famotidine

( 7.1 ) • Tizanidine (CYP1A2) Substrate: Potential for substantial increases in blood concentrations of tizanidine resulting in hypotension, bradycardia or excessive drowsiness; avoid concomitant use, if possible. 7.2 Tizanidine (CYP1A2 Substrate) Although not studied clinically, famotidine is considered a weak CYP1A2 inhibitor and may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate. Refer to the full prescribing information for tizanidine.

Mechanism: Famotidine can slow down the body's ability to clear tizanidine, which may lead to dangerously high levels of the drug in your blood.

7.2 Moderate or Weak CYP1A2 Inhibitors Concomitant use of tizanidine with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided.

Mechanism: Acyclovir blocks a specific liver enzyme that breaks down tizanidine. This causes the muscle relaxant to stay in your body at much higher levels, which can be dangerous.

7.2 Moderate or Weak CYP1A2 Inhibitors Concomitant use of tizanidine with moderate or weak CYP1A2 inhibitors (e.g., zileuton, antiarrhythmics [amiodarone, mexiletine, propafenone, and verapamil], cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided.

Mechanism: Verapamil slows down the liver process that clears tizanidine from your body, which can lead to higher drug levels.

Check all your medications →

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

Can I drink alcohol while taking tizanidine?
No, alcohol can increase the sleepiness caused by tizanidine.
What should I do if I feel dizzy after taking tizanidine?
Lie down until the dizziness passes. Be careful when standing up.
Can I drive while taking tizanidine?
Tizanidine can cause sleepiness, so be careful driving or operating machinery until you know how it affects you.
Will tizanidine cure my spasticity?
Tizanidine helps to manage spasticity symptoms, but it is not a cure.
How long does it take for tizanidine to start working?
Tizanidine starts working quickly, but the effects last only a short time.
Can I take tizanidine with other medicines?
Talk to your doctor about all the medicines you take, especially those that lower blood pressure or cause sleepiness.
What happens if I take too much tizanidine?
Seek medical attention immediately. Overdoses can cause serious side effects.
How will I know if tizanidine is working?
You should notice a decrease in muscle stiffness and spasms.
Can I switch between the tablet and capsule forms of tizanidine?
The tablet and capsule forms are absorbed differently. Talk to your doctor before switching.
What tests will my doctor do while I'm taking tizanidine?
Your doctor will check your liver function with blood tests.
What are the common side effects of tizanidine?
The registry lists Dry mouth, Sleepiness, Weakness, Dizziness among the most-reported FAERS reaction terms for tizanidine. The compiled record contains 22,750 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does tizanidine interact with other medications?
The registry has 17 documented interaction rows for tizanidine. Notable source-record pairings include ciprofloxacin, fluvoxamine, famotidine. These rows are not a complete medication review.
What drug class is tizanidine?
tizanidine belongs to the Central Alpha-2 Agonist (Muscle Relaxant) drug class. It requires a prescription (Rx). Tizanidine is used to treat spasticity in adults.
What pregnancy or breastfeeding source fields are listed for tizanidine?
The FDA label for tizanidine contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.
Has tizanidine been recalled?
There is 1 recall associated with tizanidine products. Failed dissolution specification: Out of specification results observed in 24-month long term stability testing. Check the recalls section below for full details and affected products.

Active Recalls

Class II June 21, 2023

Failed dissolution specification: Out of specification results observed in 24-month long term stability testing.

Dr Reddy's Laboratories Limited

Other drugs grouped near tizanidine - same-class peers and common alternatives.

Compare tizanidine vs baclofen side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for tizanidine: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on tizanidine

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for tizanidine

The FDA label for tizanidine (sold under brand names such as Zanaflex) classifies it as a prescription-only medication in the Central Alpha-2 Agonist (Muscle Relaxant) class. Tizanidine is used to treat spasticity in adults. Official labeling lists 4 commonly reported side effects, including Dry mouth, Sleepiness, Weakness.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 22,750 voluntary reports. The database also lists 17 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS shows a generic unit cost of $0.08.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history (currently 1 recall record on file), and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: March 11, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page